FILING ANALYSIS · MONDAY, NOVEMBER 9
Compass Therapeutics, Inc. CMPX — 8-K: Results of Operations and Financial Condition
neutral
Compass Therapeutics reported $163 million in cash and marketable securities, which is expected to fund operations into 2028, and provided updates on its pipeline assets, including preparations for a BLA submission for tovecimig and ongoing cohort expansions for CTX-8371 and CTX-10726, but there are no quantified surprises in the filing.
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →